Perspectives and challenges of antioxidant therapy for atrial fibrillation

Naunyn Schmiedebergs Arch Pharmacol. 2017 Jan;390(1):1-14. doi: 10.1007/s00210-016-1320-9. Epub 2016 Nov 29.

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia associated with significant morbidity and mortality. The mechanisms underlying the pathogenesis of AF are poorly understood, although electrophysiological remodeling has been described as an important initiating step. There is growing evidence that oxidative stress is involved in the pathogenesis of AF. Many known triggers of oxidative stress, such as age, diabetes, smoking, and inflammation, are linked with an increased risk of arrhythmia. Numerous preclinical studies and clinical trials reported the importance of antioxidant therapy in the prevention of AF, using vitamins C and E, polyunsaturated fatty acids, statins, or nitric oxide donors. The aim of our work is to give a current overview and analysis of opportunities, challenges, and benefits of antioxidant therapy in AF.

Keywords: Antioxidants; Atrial fibrillation; Atrial remodeling; Gene therapy; Oxidative stress; Prevention.

Publication types

  • Review

MeSH terms

  • Action Potentials
  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Antioxidants / therapeutic use*
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / genetics
  • Atrial Fibrillation / metabolism
  • Atrial Fibrillation / physiopathology
  • Atrial Remodeling / drug effects
  • Genetic Therapy / methods
  • Heart Atria / drug effects*
  • Heart Atria / metabolism
  • Heart Atria / physiopathology
  • Heart Rate / drug effects*
  • Humans
  • Oxidative Stress / drug effects*
  • Oxidative Stress / genetics
  • Risk Factors

Substances

  • Anti-Arrhythmia Agents
  • Antioxidants